2025
Years of life lost due to central nervous system tumor subtypes in the United States
Gerstl J, Price M, Bernstock J, Kruchko C, Spanehl L, Karandikar P, Barnholtz-Sloan J, Smith T, Claus E, Ostrom Q. Years of life lost due to central nervous system tumor subtypes in the United States. Neuro-Oncology 2025, noaf142. PMID: 40517297, DOI: 10.1093/neuonc/noaf142.Peer-Reviewed Original ResearchYears of Life LostMalignant CNS tumorsMean YLLCNS tumorsCentral nervous systemNational Program of Cancer RegistriesNon-malignant CNS tumoursNational Vital Statistics SystemVital Statistics SystemCentral nervous system tumor subtypeDisease burden measuresNon-malignant meningiomasLife expectancy dataPediatric CNS malignanciesYears of lifeMalignant pediatric tumorsNon-malignant tumorsAge of deathCancer RegistryIndividual patient levelLife LostPremature mortalityTumor histopathologiesPrimary brainCNS malignanciesAssessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework
Kurz S, Renovanz M, Bitzer M, Niyazi M, Malek N, Tatagiba M, Tabatabai G. Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. Neuro-Oncology Advances 2025, 7: vdaf127. PMID: 40980453, PMCID: PMC12445679, DOI: 10.1093/noajnl/vdaf127.Peer-Reviewed Original ResearchNeuro-oncology studiesClinical benefitPatient cohortRandomized phase 3 clinical trialESMO-Magnitude of Clinical Benefit ScalePhase 3 clinical trialsMagnitude of Clinical Benefit ScaleMagnitude of clinical benefitProspective assessmentComprehensive molecular profilingSingle-arm studyAssessment of clinical outcomesTargeted therapy recommendationsClinically relevant toolASCO Value FrameworkTreatment-related burdenAmerican SocietyLongitudinal observational studyCNS malignanciesMedical therapyTreatment cohortsClinical outcomesRadiographic outcomesTreatment responseAntitumor therapy
2016
The Role of Laser-Induced Thermal Therapy in the Management of Malignant Gliomas
Fomchenko E, Chiang V. The Role of Laser-Induced Thermal Therapy in the Management of Malignant Gliomas. 2016, 103-119. DOI: 10.1007/978-3-319-49864-5_7.Peer-Reviewed Original ResearchLaser interstitial thermal therapyHigh-grade gliomasSurgical resectionUse of LITTCommon primary CNS malignancyRecurrent high-grade gliomaOverall treatment algorithmPrimary CNS malignanciesRole of LITTPoor surgical candidatesStandard surgical approachDe novo diagnosisDeep gray nucleiInterstitial thermal therapyLaser thermal ablationAggressive treatmentCNS malignanciesSurgical candidatesImproved survivalInitial diagnosisSignificant morbidityTreatment algorithmMulticenter studySurgical approachBasal ganglia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply